Listen and follow our podcasts on:

This educational programme is supported by an Independent Educational Grant from Bayer.

In this podcast, Dr Tracy Stockley and Prof. David Hong come together to provide an introduction to molecular testing.

Listen as they discuss:

  • Why identifying genetic alterations is so important
  • How targeted therapies impact outcomes
  • When to use molecular profiling
  • Which methods of genetic testing to choose

 

Clinical takeaways

 

  • Identification of actionable genetic alterations and treatment with an associated targeted therapy can achieve significant outcomes for cancer patients

  • Molecular profiling should be routine both at the point of diagnosis and at progression for cancer patients wherever possible

  • Tumour biopsy is the gold standard for genetic testing, but ctDNA can be an alternative for tumours that are difficult to biopsy and also is associated with a faster turnaround time

Dr Stockley is the Head of the Department of Clinical Laboratory Genetics at the University Health Network in Toronto. The Department is the largest molecular pathology laboratory service in Canada and consists of two labs, the translational Advanced Molecular Diagnostics Laboratory at the Princess Margaret Cancer Center, and the clinical Genome Diagnostics Laboratory at Toronto General Hospital. Dr Stockley’s role at UHN includes oversight of genetic testing for oncology including companion diagnostics, genomic test development for clinical laboratory use, and applications of next-generation sequencing to clinical care. Dr Stockley has an interest in quality improvement related to high-complexity laboratory testing, and has participated in standard development for molecular diagnostics with multiple national and international organizations including Health Canada, Clinical Laboratory Standards Institute (CLSI), European Molecular Quality Network and the International Organization for Standardization (ISO). Dr Stockley is an Associate Professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto, and the current President of the Canadian College of Medical Geneticists.

Dr Tracy L Stockley has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, Bayer, Bristol Myers Squibb and Janssen.

Dr David S. Hong is a Professor, Deputy Chairman in the Department of Investigational Cancer Therapeutics (Phase I Program), Clinical Medical Director of the Clinical Translational Research Center (CTRC), and Associate Vice President of Clinical Research at The University of Texas MD Anderson Cancer Center.

Dr Hong was instrumental in forming one of the largest and most innovative Phase 1 clinical trial units in the world, with over 1300 patients enrolled in clinical trials in FY2021 and over 400 active ongoing clinical trials.

Dr Hong has been the Principal Investigator of over 120 research protocols that involve a wide range of sponsors, including the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute. He has published over 374 publications in Peer-reviewed Journals such as NEJM, Lancet Oncology, JCO and Nature.

He has been involved in the early development of cabozantinib, siltuximab, dabrafenib, trametinib, regorafenib, lenvatinib, larotrectinib, tesotumab vendotin, and sotorasib the first drug to target KRAS that have led to FDA approval.

He has also helped found 2 companies OncoResponse and Telperian.

He is an expert on c-Met, NTRK, KRAS, and adoptive cellular therapy in solid tumors and has led several national trials such as the c-Met amplified, c-Met exon 14 deleted, and NTRK arms of the NCI-MATCH trial. He been awarded the ASCO Young Investigator Award, the Jesse Jones award, Best Boss award at MD Anderson, Irwin Krakoff Award for Clinical Research, and the Gerald P. Bodey award for education and Mentor of the year award in the Division of Cancer Medicine, MD Anderson.

Prof. David Hong has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AbbVie, Adaptimmune, Adlai-Nortye, Amgen, Astra-Zeneca, Bayer, Bristol- Myers Squibb, Daiichi-Sankyo, Deciphera, Eisai, Endeavor, Erasca, F. Hoffmann- LaRoche, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa Kirin, Lilly, LOXO, Merck, Medimmune, Mirati, Mologen, Navier, NCI-CTEP, Novartis, Numab, Pfizer, Pyramid Bio, SeaGen, Takeda, TCR2, Teckro, Turning Point Therapeutics and VM Oncology.

Programme summary
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer and Pierre Fabre Laboratories.

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast
Hemostasis and bleeding disorders Oncology 
Postępowanie w przypadku zakrzepicy – seria podcastów

Uznani eksperci dzielą się swoimi spostrzeżeniami. Kliknij na odpowiednią zakładkę, aby wybrać odcinek podcastu.

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
Highlights from ASCO GI 2025

Expert insights on BRAF-mutated colorectal cancer

Experts
Dr Elena Élez
Endorsed by
DiCE
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025

Educational programme supported by an Independent Educational Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. This content is intended for HCPs outside the UK and ROl only.
podcast Podcast

Episode

4

of 4

episode
Oncology 
HCC podcast series part 4: Intermediate HCC – the evolving role of IO

Integrating multimodal approaches with multidisciplinary care

Experts
Dr Edward Kim, Dr Nina Sanford, Dr Mark Yarchoan, Oncology Brothers (Moderators)
Endorsed by
Blue Faery plus Global Liver Institute DiCE
ELPA
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.
video Video
Oncology 
The evolving role of liquid biopsy in HR+/HER2- metastatic breast cancer

Exploring the impact of liquid biopsy in advanced breast cancer

Experts
Prof. Frédérique Penault-Llorca, Dr Aditya Bardia
Endorsed by
ISLB
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Thermo Fisher Scientific.
animated-video Animated Video
Oncology Obstetrics and Gynecology 
Current treatment options in advanced/recurrent endometrial cancer

Exploring the impact of molecular subtypes 

Experts
Prof. Christian Marth
  • download Downloadable
    Resources
  • clock 7 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of or speakers involved in this programme.
podcast Podcast

Episode

3

of 4

episode
Oncology 
HCC podcast series part 3: Intermediate HCC – treatment options and strategies

Expert insights on systemic, loco-regional, and multimodal therapies

Experts
Dr Maria Reig, Dr Emil I Cohen, Oncology Brothers (Moderators)
Endorsed by
DiCE Blue Faery plus Global Liver Institute
ELPA
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Bayer.